Completed PHASE3 INTERVENTIONAL 2-arm NCT03901352

Study of Mirogabalin for Central Neuropathic Pain

An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension

Sponsor: Daiichi Sankyo Co., Ltd.

Conditions Central Neuropathic Pain

Interventions Mirogabalin Placebo

Updated 19 times since 2019 Last updated: Oct 8, 2024 Started: Mar 12, 2019 Primary completion: Dec 28, 2020 Completion: Dec 28, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03901352, this PHASE3 trial focuses on Central Neuropathic Pain and remains completed. Sponsored by Daiichi Sankyo Co., Ltd., it has been updated 19 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

19 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Nov 2024 — Sep 2025 [monthly]

Completed PHASE3
Oct 2024 — Nov 2024 [monthly]

Completed PHASE3
Sep 2024 — Oct 2024 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3

▶ Show 14 earlier versions

Mar 2024 — Jul 2024 [monthly]

Completed PHASE3
Mar 2021 — Mar 2024 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jan 2021 — Mar 2021 [monthly]

Active Not Recruiting PHASE3
Jul 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Apr 2020 — Jul 2020 [monthly]

Recruiting PHASE3
Mar 2020 — Apr 2020 [monthly]

Recruiting PHASE3
Feb 2020 — Mar 2020 [monthly]

Recruiting PHASE3
Dec 2019 — Feb 2020 [monthly]

Recruiting PHASE3
Nov 2019 — Dec 2019 [monthly]

Recruiting PHASE3
Oct 2019 — Nov 2019 [monthly]

Recruiting PHASE3
Sep 2019 — Oct 2019 [monthly]

Recruiting PHASE3
Aug 2019 — Sep 2019 [monthly]

Recruiting PHASE3
Jul 2019 — Aug 2019 [monthly]

Recruiting PHASE3
May 2019 — Jul 2019 [monthly]

Recruiting PHASE3

First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo Co., Ltd.

Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Aomori, Japan , Chiba, Japan , Daegu, South Korea , Daejeon, South Korea , Ehime, Japan , Fukui, Japan , Fukuoka, Japan , Fukushima, Japan , Gunma, Japan and 42 more locations